3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Kilpest India — Investor Presentation (July 2020)
41 slides from 3b Blackbio Dx's investor presentation, Jul 31, 2020
Slide 1: Cover letter to Bombay Stock Exchange
- sIc ~ •• QUAUTl' CB1IIICI1IOI 10 .001 . 2000 KILPEST INDIA LIMITED REGD.OFFICE & FACTORY: 7-C. INDUSTRIAL AREA. GOVINDPURA. BHOPAL - 462 023 INDIA Tel E·mail: : 91-7552586536.2586537 kilpest@bsnLin kilpestbpl@yahoo.co.in FAX NO. : 91-755 2580438 Visit us at : www.kilpest.com CIN : L24211MP1972PLC0
Slide 2: Investor Presentation July 2020
Farmer’s trusted Agro-input partner for 48 years Reliable & affordable healthcare diagnostic solutions INVESTOR PRESENTATION July’ 2020
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to
Slide 4: Kilpest Existing Products
Kilpest Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides - 70 • Bio pesticide - 07 • Antibacterials - 01 • Bio fungicide - 01 • Fungicides - 15 • Bio fertilizers - 05 • Herbicides - 11 • Bio nematicides - 01 • Public Health - 11 • Public Health - 02 • Microferti
Slide 5: Business Overview and Strengths
Business Overview and Strengths Experienced team & state of art facility located in center of India- with GST implementation this should give a boost to the company • 48 yrs old Pesticide Formulation Company, well established in central India, strong brand equity in central India especially in Madhy
Slide 6: Financial Performance: Key Highlights
Financial Performance : Key Highlights 5288.98 KILPEST (Consolidated) Q1F21 Q1 F20 839.65% 3626.37 1745.20% Net sales 5288.98 562.87 Q1F21 Profit before tax 3626.37 196.53 Q1F20 Profit after tax 2719.68 142.03 562.87 196.53 Paid up Equity share capital 750.81 750.81 Revenue PBT Reserves 1636.39 1133
Slide 7: Present Market Overview/Outlook
Present Market Overview/Outlook • Sales during the first quarter remains very low due to non-season & is similar to last year first quarter. • Company will continue to focus on Public Health/warehousing sector and exports. As due to COVID-19, Private agriculture market is uncertain. Detailed Present
Slide 8: From the house of Kilpest India Ltd.
Since 1972 From the house of Kilpest India Limited, KILPEST INDIA India’s most trusted agro-chemical brand proudly brings LTD. First licensed Molecular Diagnostics (IVD) manufacturing facility in India under Medical Device Rule 2017 ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I
Slide 9: 3B BlackBio Biotech India Limited
From the house of KILPEST India Ltd. 3B BlackBio Biotech India Limited; has become India’s leading healthcare company specialized in the development of molecular biology fine-chemicals as tools for diagnostic/ pathology segment of healthcare. The Company is CDSCO Licensed, ISO 13485:2016 certified,
Slide 10: TRUPCR Vision and Mission
TRUPCR® from 3B BlackBio Biotech (I) Ltd. Vision Reliable and affordable healthcare solutions for all Mission 3B BlackBio Biotech (I) Ltd. with its TRUPCR® brand of products is committed to design and develop molecular diagnostics products of superior quality and value that continuously improves the
Slide 11: Timeline & Milestones
Timeline & Milestones Extending Launching Menu with Onco-panels panels Launch of Solid Tumor AML Tropical fever Extending ALL panel Menu with EGFR MPN Hemato-onco Adding Virology & KRAS panels Virology Public Health Acquisition Entering & Expanding of NGS Developing Oncology & Menu HBV, HCV NGS pane
Slide 12: Growth Canvas
Growth Canvas Sales (Rs. In Lakhs) Customers ₹1,800.00 200 ₹1,600.00 ₹1,536.00 180 160 ₹1,400.00 140 ₹1,200.00 ₹1,118.93 120 ₹1,000.00 100 ₹800.00 ₹765.05 80 ₹600.00 60 ₹400.00 ₹315.89 40 ₹200.00 ₹164.56 ₹94.56 ₹100.73 20 ₹0.00 0 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 Sales (Rs. In
Slide 13: Organization Structure
Organization Structure Managing Director Director Finance Head Commercial Production Scientist General Head – R&D QC Manager Export Manager Operations/ Exclusive Account Dept. Manager Bioinformatics Manager Channel Partner Scientist – Kit Documentation Logistics Regional Manager – South Senior Scien
Slide 14: Financial Highlights Q1-FY21
Financial Highlights Q1-FY21 1447.40% 3614.31 1688.82% 5016.84 324.21 202.05 Revenue EBITDA 3604.81 2702.27 1752.90% 1824.42% Q1FY21 Q1FY20 194.55 140.42 Rs. In Lakhs. PBT PAT ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 15: Events related to COVID-19
Events related to COVID-19 1. The company got approval from ICMR on 2nd April, 2020 and license from CDSCO on 4th April, 2020 for selling RT-PCR Kit for COVID-19, under its brand name TRUPCR® SARS-CoV-2 RT qPCR Kit (Real-Time PCR based detection of SARS-CoV-2 virus) Version 2.0, This test comes with
Slide 16: Events related to COVID-19
Events related to COVID-19 Indian Council for Medical Research (ICMR) has given order through HLL Infratech Services Ltd, (HITES), Noida- • TRUPCR® Viral RNA Extraction Kit- 5,00,000 (Five Lacs) tests to be used for testing of COVID-19 (Novel Corona Virus) from HLL Infratech Services Ltd. (HITES), t
Slide 17: Events related to COVID-19: US FDA Emergency Use Authorization
Events related to COVID-19 US FDA Emergency Use Authorization On 19th June 2020, 3B Blackbio Biotech India Ltd. becomes first ever Indian molecular diagnostics company to receive US FDA (EUA). Especially at times when more and more reliable testing is the need of the hour for India as well as other
Slide 18: Tests sold in July'20
Tests sold in July’20 We have sold in the month of July’20 (as on 30 July, 2020) 16,11,800 (Sixteen Lacs Eleven Thousand Eight Hundred) Tests and increase our customer base to over 100 customers. Total number of tests sold till 30 July, 2020 is 24,97,800 (Twenty Four Lacs Ninety Seven Thousand Eight
Slide 19: July'20 update COVID-19
July’ 20 update COVID-19… Completion of Order We are pleased to inform you that company has successfully completed the government orders received in the month of June’20 to the complete satisfaction of the customers. The TRUPCR® kits were spread over 300 labs across the nation and we are proud to sa
Slide 20: July'20 update COVID-19
…July’ 20 update COVID-19 Current Private Market Status We can proudly say that TRUPCR® is the most preferred brand of COVID-19 Kit amongst over 100 Labs in India. At most of the places we have been preferred over foreign reputed brands. We are regularly getting orders from these Pvt. labs. Current
Slide 21: Our Beneficiaries
Our Beneficiaries FOR PATIENTS FOR LABORATORIES CLINICALLY VALIDATED PRECISE TRUPCR® kits are calibrated to WHO standards and clinically validated TRUPCR® offers highly sensitive and precise qPCR assays as on wide variety and numbers of samples. indicated by minimum variability of replicates and mul
Slide 22: Work Process
Work Process PLAN RESEARCH Feasibility DESIGN DEVELOP VALIDATIONS APPROVALS COMMERCIALIZATION (Technical & Commercial) IMPROVEMENT SUPPORT ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 23: R&D
R&D People • Highly educated team of scientist from varied backgrounds • Dedicated teams for respective segments • Separate onco team headed by researchers (Ph.Ds.) from oncology background • Separate team for infectious parameters headed by researchers (Ph.Ds.) from infectious diseases background L
Slide 24: Product QC – Our Strength
Product QC – Our Strength All TRUPCR® products are passed through stringent QC protocols to ensure optimal performance at customer site • QC of raw material • QC of every final lot • Cherrypicked QC of final batch Besides above routine QC practices, Kits are QC checked on respective* real-time cycle
Slide 25: Our Certificates
Our Certificates US FDA EUA COVID-19 RT-PCR Kit CDSCO Licensed Diagnostic Kits ISO 13485:2016 Certified Company ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 26: Technology Focus
Technology Focus High Volume Cytogenetics Real-Time PCR 3B’s Focus Low Growth High Growth Other Molecular Techniques Sanger Sequencing Next Generation Mass Spec Sequencing Hybridization Microarray Low Volume ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 27: Molecular Diagnostics
Molecular Diagnostics • The process of identifying a disease by studying molecules, such as proteins, DNA, and RNA, in a tissue or fluid. • Molecular diagnostics is a technique used to analyze biological markers in the genome and proteome—the individual’s genetic code and how their cells express the
Slide 28: Source-https://www.gminsights.com/pressrelease/molecular-diagnostics-market-size
Source-https://www.gminsights.com/pressrelease/molecular-diagnostics-market-size
Slide 29: Product Segments
Product Segments Molecular Microbiology Molecular Oncology Human Genetics SYNDROMES & INFECTIONS CANCERS DISORDERS Individual Markers Individual Markers Individual Markers Infectious Panels Oncology Panels Genetic Panels ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALT
Slide 30: All-Inclusive TRUPCR products
All-Inclusive TRUPCR® products TRUPCR range of products offers end-to-end standardized solutions from samples to optimized end-results Nucleic Acid Detection Sample Nucleic Acid Nucleic Acid Extraction & and Management Preparation Amplification Purification Analysis TRUPCR Nucleic Acid Extraction ki
Slide 31: Next Generation Sequencing Assays
Next Generation Sequencing Launching soon… Next Generation Sequencing Assays Real image of NGS facility at 3B BlackBio Biotech (I) Ltd. Bhopal, India ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 32: Our National Presence
Our National Presence TRUPCR® range of products are currently used by: 180+ customers Across 50 Cities ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH
Slide 33: Our Global Presence
Our Global Presence TRUPCR® Kits are now regularly exporting in Neighbouring Countries, UK, South East Asia, Middle East and East Africa Product Validation successfully completed & order received in UK Product Validation is in advanced stage in USA Product Validation & Price negotiation in Africa, S
Slide 34: New Products Launched in Q1 2020-21
New Products Launched in Q1 2020-21 TRUPCR® PIK3CA Mutation Kit Qualitative Detection of PIK3CA Mutations on real-time PCR TRUPCR® IDH1/2 Detection Kit Detection of IDH1 and IDH2 mutations using real-time PCR TRUPCR® Gastro Panel Kit Detection of mutations in the IDH1 and IDH2 genes using real-time
Slide 35: Target Customer Segments
Target Customer Segments Indian IVD/MDx Market Hospital Labs Stand-alone Pharma Labs Govt. Private Pathologist(s) Corporate CLINICAL Hospitals Hospitals Labs Labs TRIALS Secondary Central Govt. State Govt. Targeted Corporate Other Private National Regional National Labs Regional Labs Hospitals Hospi
Slide 36: TRUPCR Global Recognition
TRUPCR® Global Recognition Complete Includes Simultaneous Location of workflow Reverse Alignment step for Major Company Sensitivity Company solution Transcriptase with IS and Minor available step design transcript France, Europe Elitech - PCR alert kit MR4.0 ✗ ✗ WHO ✗ 3B BlackBio - TRUPCR® INDIA MR4
Slide 37: Contractual Business
Contractual Business • We are happy to inform that the Company to ensure long term assured business, has started signing long term (2-3 yr) contract with large customers. • As on date the company has six contracts running out of which 1 has been executed in this quarter which ensures yearly business
Slide 38: Growth Drivers
Growth Drivers • Improvement in Indian healthcare industry with high demand in medical tourism • Increasing number of molecular tests being introduced by labs External Growth • Evolution of disease profiles. New viruses and cancers are been diagnosed • Increase in evidence-based treatments / Drug re
Slide 39: National MSME Award 2018
National MSME Award- 2018 by Hon'ble President of India, Shri Ram Nath Kovind. Hon'ble President of India, Shri Ram Nath Kovind on Friday on the occasion of 20th National Technology Day presented the national award for successful commercialization of indigenous technology at Vigyan Bhavan, New Delhi
Slide 40: Outstanding Achievement Award for Excellence in R&D
Outstanding Achievement Award for Excellence in R&D by FMPCCI, Bhopal. 3B BLACKBIO BIOTECH (I) LTD. Bhopal is awarded with the ‘Outstanding Achievement Award in recognition of excellence in R&D through technology in MSME enterprise category’, during the 4th Outstanding Achievement Award 2016, held o
Slide 41: Thank You
Thank You ONCOLOGY I INFECTIOUS DISEASES I WOMEN’S HEALTH I HUMAN GENETICS I PUBLIC HEALTH